3 ms·
The specific mechanism Mylan markets is covered by a patent. Some adjustment to the way the needle cap operates. Of course that patent doesn't prevent other ep
by maxerickson 9y ago
The specific mechanism Mylan markets is covered by a patent. Some adjustment to the way the needle cap operates.
Of course that patent doesn't prevent other epinephrine autoinjectors from coming to market (and Adrenaclick is available in the US, including a couple generics).
My take is that the FDA should have some authority to deny market approval for such small improvements if the company refuses to license them to generic manufacturers. The hard part is deciding what constitutes a small improvement.